COLLABORATIONS

  ›  Collaborations  »  Partnering Strategy Process & Media development   |  Our Partners

Partnering strategy

Partnering strategy

Accellta develops customized processes, protocols and corresponding media for culturing stem cells in 3D suspension, under feeder-free, adherent-free conditions.

These solutions dramatically reduce the time and cost of stem cell manufacturing and enable the culturing of high quantities and densities of stem cells (>40 million cells/ml) of consistent, well-defined and homogeneous cell population.

The company enjoys a rich IP portfolio and has already completed several agreements with multi-national companies. The intellectual property assets of Accellta include a portfolio of patents pertaining to novel techniques and products, including:

  • Pluripotent stem Cell culturing
  • Growth media for feeder-free culturing of hPSC
  • Stem Cell expansion in suspension
  • Stem Cell culturing as single-cells in bioreactors
  • Stem-Cell controlled differentiation
  • Medium formulation
  • Human foreskin-derived feeder cells

Accellta maintains a state of the art facility that includes GMP-compliant clean rooms, laboratories and offices with a total area of 6000 sq.f.
The company regularly partners with biopharma and cell research companies to developing custom-made solutions for pluripotent stem cells and stem cell-derived differentiated cells, such as neurons, cardiomyocytes and hepatocytes for research, drug screening, drug development and clinical trials.  The company is always interested in establishing new dialogues.

Ask Us About

Partnering strategy


 

Please fill the required field.
Please fill the required field.

Atlas of Human Pluripotent Stem Cells

978 1 61779 548 0

Editors:

Michal Amit, Joseph Itskovitz-Eldor

Image

Accelerating stem cell technologies

Terms of use | Privacy Policy  |  © 2021

© 2021 Accellta. All Rights Reserved. Designed By Netron Israel Ltd.

Image

Register / Login